Drug interactions
Encorafenib + Nilotinib
Severity: Major
Encorafenib and Nilotinib: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Encorafenib is a CYP3A4 substrate, and nilotinib is a weak to moderate CYP3A4 inhibitor, so encorafenib exposure may rise. Both drugs also prolong the QT interval, so the combination adds to the risk of torsades de pointes.
What this interaction means in plain words
Encorafenib and Nilotinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Encorafenib belongs to Oncology; Nilotinib belongs to Oncology.
Why it happens
Nilotinib inhibits CYP3A4, raising encorafenib levels, together with additive QT prolongation.
What to do
Avoid the combination where an alternative exists. If it is necessary, reduce the encorafenib dose per labeling for moderate CYP3A4 inhibitors and monitor ECG and electrolytes.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Encorafenib and Nilotinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Nilotinib
- Amiodarone + Nilotinib Contraindicated
- Arsenic trioxide + Nilotinib Contraindicated
- Disopyramide + Nilotinib Contraindicated
- Dofetilide + Nilotinib Contraindicated
- Dronedarone + Nilotinib Contraindicated
- Droperidol + Nilotinib Contraindicated
Other interactions of Encorafenib
Frequently asked questions
Can I take Encorafenib with Nilotinib?
MediHelp rates the interaction as major. Encorafenib and Nilotinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Encorafenib is a CYP3A4 substrate, and nilotinib is a weak to moderate CYP3A4 inhibitor, so encorafenib exposure may rise. Both drugs also prolong the QT interval, so the combination adds to the risk of torsades de pointes.
How serious is the interaction between Encorafenib and Nilotinib?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid the combination where an alternative exists. If it is necessary, reduce the encorafenib dose per labeling for moderate CYP3A4 inhibitors and monitor ECG and electrolytes.
What other medicines interact with Nilotinib?
MediHelp also lists interactions of Nilotinib with, for example, Amiodarone, Arsenic trioxide, Disopyramide. The full list is on the Nilotinib page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
